CN107001368B - 具有多重模式抗疼痛活性的1,9-二氮杂螺环十一烷化合物 - Google Patents

具有多重模式抗疼痛活性的1,9-二氮杂螺环十一烷化合物 Download PDF

Info

Publication number
CN107001368B
CN107001368B CN201580062701.0A CN201580062701A CN107001368B CN 107001368 B CN107001368 B CN 107001368B CN 201580062701 A CN201580062701 A CN 201580062701A CN 107001368 B CN107001368 B CN 107001368B
Authority
CN
China
Prior art keywords
unsubstituted
compound
alkyl
substituted
hydrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201580062701.0A
Other languages
English (en)
Chinese (zh)
Other versions
CN107001368A (zh
Inventor
玛丽娜·威吉里-贝纳德欧
卡洛斯·阿勒格雷特-默里纳
卡门·阿曼萨-罗萨勒斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Esway Pharmaceuticals AG
Original Assignee
Esway Pharmaceuticals AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Esway Pharmaceuticals AG filed Critical Esway Pharmaceuticals AG
Publication of CN107001368A publication Critical patent/CN107001368A/zh
Application granted granted Critical
Publication of CN107001368B publication Critical patent/CN107001368B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/20—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/10—Spiro-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
CN201580062701.0A 2014-11-21 2015-11-20 具有多重模式抗疼痛活性的1,9-二氮杂螺环十一烷化合物 Expired - Fee Related CN107001368B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14382466 2014-11-21
EP14382466.2 2014-11-21
PCT/EP2015/002333 WO2016078771A1 (en) 2014-11-21 2015-11-20 1,9-diazaspiro undecane compounds having multimodal activity against pain

Publications (2)

Publication Number Publication Date
CN107001368A CN107001368A (zh) 2017-08-01
CN107001368B true CN107001368B (zh) 2019-05-31

Family

ID=51982510

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201580062701.0A Expired - Fee Related CN107001368B (zh) 2014-11-21 2015-11-20 具有多重模式抗疼痛活性的1,9-二氮杂螺环十一烷化合物

Country Status (7)

Country Link
US (1) US10022359B2 (enExample)
EP (1) EP3221315A1 (enExample)
JP (1) JP2017535566A (enExample)
CN (1) CN107001368B (enExample)
CA (1) CA2967857A1 (enExample)
MX (1) MX2017006513A (enExample)
WO (1) WO2016078771A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201615643A (zh) 2014-06-02 2016-05-01 伊史帝夫博士實驗室股份有限公司 具有多重模式抗疼痛活性之１－氧雜－４，９－二氮雜螺十一烷化合物之烷基與芳基衍生物
US10689398B2 (en) 2015-10-23 2020-06-23 Esteve Pharmaceuticals, S.A. OXA-Diazaspiro compounds having activity against pain
WO2018153545A1 (en) * 2017-02-27 2018-08-30 Laboratorios Del Dr. Esteve, S.A. Piperidine methanone derivatives having multimodal activity against pain
AU2021325431B2 (en) * 2020-08-14 2024-01-18 Novartis Ag Heteroaryl substituted spiropiperidinyl derivatives and pharmaceutical uses thereof
WO2024105225A1 (en) 2022-11-18 2024-05-23 Universitat De Barcelona Synergistic combinations of a sigma receptor 1 (s1r) antagonist and a soluble epoxide hydrolase inhibitor (sehi) and their use in the treatment of pain

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101835784A (zh) * 2007-06-20 2010-09-15 埃斯蒂文博士实验室股份有限公司 作为用于治疗精神病症的西格玛受体的抑制剂的螺[哌啶-4,4'-噻吩并[3,2-c]吡喃]衍生物及其相关化合物
EP2251317A1 (en) * 2009-05-15 2010-11-17 CHEMI S.p.A. Method for preparing fesoterodine and/or fesoterodine fumarate
WO2014117920A1 (en) * 2013-02-04 2014-08-07 Merck Patent Gmbh Spiro-quinazolinone derivatives useful for the treatment of neurological diseases and conditions

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993013101A1 (fr) * 1991-12-27 1993-07-08 Yoshitomi Pharmaceutical Industries, Ltd. Compose de pyridonecarboxylate, son utilisation pharmaceutique et compose spiro
GB9202238D0 (en) * 1992-02-03 1992-03-18 Wellcome Found Compounds
US6790854B2 (en) * 2000-03-24 2004-09-14 Meiji Seika Kaisha, Ltd. Diphenylalkylamine derivatives useful as opioid receptor agonists
ES2251317B1 (es) * 2004-10-14 2007-03-16 Laboratorios Del Dr. Esteve, S.A. Inhibidores del receptor sigma.
US20120101110A1 (en) * 2010-10-26 2012-04-26 Sangamesh Badiger Diaza-spiro[5.5]undecanes
JP6498672B2 (ja) * 2013-12-20 2019-04-10 エステベ ファーマシューティカルズ, ソシエダッド アノニマEsteve Pharmaceuticals, S.A. 疼痛に対して多重モードの活性を有するピペリジン化合物
TW201615642A (zh) * 2014-06-02 2016-05-01 伊史帝夫博士實驗室股份有限公司 具有多重模式抗疼痛活性的１－氧雜－４，９－二氮雜螺十一烷化合物之醯胺衍生物
CA2967097A1 (en) * 2014-11-21 2016-05-26 Laboratorios Del Dr. Esteve, S.A. Spiro-isoquinoline-1,4'-piperidine compounds having multimodal activity against pain

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101835784A (zh) * 2007-06-20 2010-09-15 埃斯蒂文博士实验室股份有限公司 作为用于治疗精神病症的西格玛受体的抑制剂的螺[哌啶-4,4'-噻吩并[3,2-c]吡喃]衍生物及其相关化合物
EP2251317A1 (en) * 2009-05-15 2010-11-17 CHEMI S.p.A. Method for preparing fesoterodine and/or fesoterodine fumarate
WO2014117920A1 (en) * 2013-02-04 2014-08-07 Merck Patent Gmbh Spiro-quinazolinone derivatives useful for the treatment of neurological diseases and conditions

Also Published As

Publication number Publication date
WO2016078771A1 (en) 2016-05-26
EP3221315A1 (en) 2017-09-27
CN107001368A (zh) 2017-08-01
MX2017006513A (es) 2018-04-11
CA2967857A1 (en) 2016-05-26
US20170354648A1 (en) 2017-12-14
US10022359B2 (en) 2018-07-17
JP2017535566A (ja) 2017-11-30

Similar Documents

Publication Publication Date Title
CN103025732B (zh) 顺式-四氢-螺(环己烷-1,1’-吡啶并[3,4-b]吲哚)-4-胺衍生物
CN107001368B (zh) 具有多重模式抗疼痛活性的1,9-二氮杂螺环十一烷化合物
CN106061969B (zh) Trpa1调节剂
TW201718533A (zh) 針對疼痛具有多模式活性的經取代的醯胺衍生物
TW201632522A (zh) 針對疼痛具有多模式活性的螺－異喹啉－１，４’－哌啶化合物
CN109526220A (zh) 用于治疗疼痛和疼痛相关的状况的四氢嘧啶并二氮杂*和四氢吡啶并二氮杂*化合物
TWI300066B (en) Pharmaceutically active compounds
JP2009535316A (ja) 二環式テトラヒドロピロール化合物
JP6884974B2 (ja) 薬物乱用の治療および薬物中毒の治療のためのオキサ−アザスピロ化合物
CN114502549B (zh) 针对疼痛具有多模态活性的高哌嗪基和高哌啶基喹唑啉-4(3h)-酮衍生物
JP6291567B2 (ja) ピラジノ［１，２−ａ］インドール化合物、その調製および医薬としての使用
CA3211638A1 (en) New 2,3-dihydro-1h-pyrrolo[3,2-b]pyridine derivatives as sigma ligands
CN109153671A (zh) 针对疼痛具有多模式活性的四氢吡喃和噻喃衍生物
WO2019121670A1 (en) 4,5-dihydro-1h-thieno[2,3-g]indazolyl derivatives having multimodal activity against pain
JP7249428B2 (ja) 疼痛に対して活性があるピペラジニル及びピペリジニルキナゾリン－４（３ｈ）－オン誘導体
JP6884973B2 (ja) 疼痛に対して活性を有するオキサジアザスピロ化合物
JP6844822B2 (ja) 疼痛に対して活性を有する置換モルホリン誘導体
BR112020008371A2 (pt) novos derivados de alcoxiamino para tratamento de dor e condições relacionadas à dor
CN117642389A (zh) 一种哌啶衍生物及其药物组合物、制备方法和用途
JP2018531263A6 (ja) 疼痛に対して活性を有するオキサジアザスピロ化合物
TW202304875A (zh) 做為Kv1.3鉀SHAKER通道阻斷劑之芳基雜環化合物
RU2833258C1 (ru) Производные гомопиперазинил- и гомопиперидинил-хиназолин-4(3H)-она, обладающие мультимодальной активностью в отношении боли
JP6891386B2 (ja) 疼痛に対して活性を有するオキサ−アザスピロ化合物
JP2009528316A (ja) シグマ受容体化合物
CN121108035A (zh) 具有Sigma-1/H3受体双靶点活性的化合物及其制备方法和应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
CB02 Change of applicant information
CB02 Change of applicant information

Address after: Barcelona

Applicant after: Esway pharmaceuticals AG

Address before: Barcelona

Applicant before: Esteve Labor Dr.

GR01 Patent grant
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20190531

Termination date: 20191120